[The State Food and Drug Administration approves the marketing of Sinovac’s iminoxiflex for injection] On November 12, the State Food and Drug Administration approved the listing of the Category 1 innovative drug iminoxifor for injection (trade name: Funokai) applied by Suzhou Sinovac Pharmaceutical Technology Co., Ltd. The indications are: hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP). This drug is indicated for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by the following Gram-negative bacteria that are sensitive to this product in patients 18 years of age and older: Klebsiella pneumoniae, Acinetobacter calcium acetate-Acinetobacter baumannii complex, Pseudomonas aeruginosa, Haemophilus influenzae, Klebsiella aerogenes, Enterobacter cloacae, Escherichia coli, and Klebsiella oxytoca. The launch of this drug provides patients with new treatment options.